Dr Bryan Day from QIMR Berghofer Medical Research Institute
in Brisbane, along with his collaborators, is responsible for the generation
and characterisation of primary glioblastoma (GBM) models, used in almost every
brain cancer research laboratory within Australia, as well as several overseas.
Brain cancer models are used to validate discoveries in the
laboratory and are absolutely essential for a discovery to progress to a
clinical trial. The development of such models is therefore an important area
of research that aims to build capacity and advance brain cancer discoveries
across the globe.
Now, Dr Day is undertaking a project to identify new drugs to combat GBM. This project has a specific focus on understanding brain cancer recurrence, as Dr Day aims to develop a unique library of paired primary and recurrent GBM models. This resource will be invaluable, and is the culmination of more than eight years of consistent research and tumour banking efforts that will greatly inform further pre-clinical studies.
This project has great importance for the research and brain
cancer community. Almost all GBM patients suffer from disease recurrence, and
in the majority of cases, the recurrent tumour is vastly different from the
primary tumour that the patient was initially treated for. Often, the recurrent
disease displays distinctly different patterns of gene expression and cells can
exhibit chemo-radiotherapy resistance. This makes it significantly harder to
treat, and as such, a greater focus is needed to study the recurrent disease, to
make long lasting changes for patients.
Dr Day and his collaborators understand the need for brain
cancer models in research, and particularly the requirement for models of this
recurrent disease. Therefore, Dr Day has made these resources available to the
research community to be used for pre-clinical discovery projects and investigations.
“We hope that these important collaborations will improve our understanding of, in particular, recurrent brain cancers and help us to develop new treatments for these aggressive tumours that claim far too many lives”, said Dr Day.
Dr Day is one of the recipients of Cure Brain Cancer Foundation’s Infrastructure Grant, receiving funding of $400,000 over four years to fund this collaborative, capacity building research.
“I am extremely grateful to the Cure Brain Cancer Foundation for their generous support”, remarked Dr Day. “This grant will allow me and my team to share our resources and technical expertise with other research teams all over Australia, meaning we will greatly accelerate the pace of brain cancer research in Australia.
Help fund vital brain cancer research